Prognostic Significance of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
TIL
cancer
head and neck cancer
prognosis
tumor-infiltrating lymphocyte
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Feb 2021
13 Feb 2021
Historique:
received:
28
01
2021
revised:
10
02
2021
accepted:
10
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
7
3
2021
Statut:
epublish
Résumé
It has been suggested that the presence of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment is associated with a better prognosis in different types of cancer. In this systematic review and meta-analysis, we investigated the prognostic role of CD4+ and CD8+ TILs in head and neck squamous cell carcinoma (HNSCC). PubMed, Cochrane, Embase, Scopus, and Web of Science were searched up to September 2020. This study was conducted following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist. Risk ratios from individual studies were displayed in forest plots and the pooled hazard ratios (HR) of death and corresponding confidence intervals (CI) were calculated according to random-effects models. Risk of bias of the included studies was assessed through the Newcastle-Ottawa scale. 28 studies met the inclusion criteria. Studies conducted on HNSCC subsites combined reported a significant reduction in the risk of death for both high CD4+ (HR: 0.77; 95% CI: 0.65-0.93) and high CD8+ TILs (HR: 0.64; 95% CI: 0.47-0.88). High CD4+ TILs were associated with significantly better overall survival among oropharyngeal HNSCC (HR: 0.52; 95% CI: 0.31-0.89), as well as high CD8+ TILS in Human papillomavirus -ve and +ve cancers (HR: 0.39; 95% CI: 0.16-0.93 and HR: 0.40; 95% CI 0.21-0.76 respectively). CD8+ TILs were also associated with improved survival in hypopharyngeal cancers (HR = 0.43 CI: 0.30-0.63). No significant association emerged for patients with cancer of the oral cavity or larynx. The findings from this meta-analysis demonstrate the prognostic significance of CD8+ and CD4+ TILs in HNSCC and variation in tumor subsite warrants further focused investigation. We highlight how TILs may serve as predictive biomarkers to risk stratify patients into treatment groups, with applications in immune-checkpoint inhibitors notable areas for further research.
Identifiants
pubmed: 33668519
pii: cancers13040781
doi: 10.3390/cancers13040781
pmc: PMC7918220
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Cancer Research UK
ID : N/A
Pays : United Kingdom
Références
Br J Cancer. 2014 Mar 18;110(6):1595-605
pubmed: 24504370
JAMA Oncol. 2016 Oct 1;2(10):1354-1360
pubmed: 27355489
Head Neck Pathol. 2011 Jun;5(2):117-22
pubmed: 21318408
Front Cell Dev Biol. 2019 Apr 09;7:52
pubmed: 31024913
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Anticancer Res. 2019 Jun;39(6):3039-3046
pubmed: 31177146
Br J Cancer. 2015 Sep 15;113(6):886-93
pubmed: 26313665
Med Oncol. 2019 Jan 21;36(2):21
pubmed: 30666437
Clin Otolaryngol. 2018 Oct;43(5):1312-1320
pubmed: 29896922
Transl Oncol. 2017 Feb;10(1):10-16
pubmed: 27888708
Eur J Cancer. 2016 Nov;67:141-151
pubmed: 27669501
Cancer Commun (Lond). 2020 Apr;40(4):135-153
pubmed: 32301585
JAMA Otolaryngol Head Neck Surg. 2019 Sep 5;:
pubmed: 31486841
Pathobiology. 2015 Sep;82(3-4):142-52
pubmed: 26330355
World J Surg Oncol. 2019 May 22;17(1):85
pubmed: 31118034
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
Cancer Med. 2019 Jan;8(1):80-93
pubmed: 30600646
Acta Otolaryngol. 2020 Mar;140(3):246-248
pubmed: 32022615
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Cancer Immunol Immunother. 2016 May;65(5):575-85
pubmed: 26993499
Int J Cancer. 2016 Jan 1;138(1):171-81
pubmed: 26178914
Eur J Cancer. 2015 Oct;51(15):2130-2143
pubmed: 26421817
Sci Rep. 2016 Nov 14;6:36956
pubmed: 27841362
Oncotarget. 2017 Aug 3;8(39):66178-66194
pubmed: 29029502
Oral Oncol. 2020 Mar;102:104560
pubmed: 31923855
Eur J Cancer. 2013 Jul;49(11):2522-30
pubmed: 23571147
J Clin Oncol. 2015 Oct 10;33(29):3293-304
pubmed: 26351330
Head Neck. 2016 Jul;38(7):1074-84
pubmed: 26879675
Cancer Immunol Res. 2018 Mar;6(3):295-304
pubmed: 29378694
Cancer Treat Rev. 2016 Jan;42:24-9
pubmed: 26547133
BMC Cancer. 2013 Dec 11;13:592
pubmed: 24330498
Br J Cancer. 2019 Apr;120(7):714-727
pubmed: 30808992
Pathology. 2017 Jun;49(4):397-404
pubmed: 28427753
Br J Cancer. 2014 Jan 21;110(2):489-500
pubmed: 24169344
J Immunol. 2019 Jan 1;202(1):278-291
pubmed: 30530592
Clin Cancer Res. 2006 Jan 15;12(2):465-72
pubmed: 16428488
Stat Med. 1999 Feb 15;18(3):321-59
pubmed: 10070677
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
J Cancer Res Clin Oncol. 2019 Jul;145(7):1761-1772
pubmed: 31115672
Clin Cancer Res. 2018 Feb 1;24(3):634-647
pubmed: 29018052
Cell. 2016 Mar 10;164(6):1233-1247
pubmed: 26967289
Oncotarget. 2017 Feb 28;8(9):14416-14427
pubmed: 28122336
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Pathol Int. 2015 Dec;65(12):644-51
pubmed: 26530981
Br J Cancer. 2014 Jan 21;110(2):501-9
pubmed: 24129245
J Clin Epidemiol. 2001 Oct;54(10):1046-55
pubmed: 11576817
Cancer Immunol Immunother. 2017 May;66(5):627-636
pubmed: 28236118
JCI Insight. 2016 Oct 20;1(17):e89829
pubmed: 27777979
Oncoimmunology. 2012 Sep 1;1(6):982-983
pubmed: 23162779
J Transl Med. 2012 Jan 03;10:1
pubmed: 22214470
Int J Cancer. 2017 Oct 1;141(7):1490-1491
pubmed: 28614904
Head Neck Pathol. 2020 Sep;14(3):689-700
pubmed: 31749124
Anticancer Res. 2017 Mar;37(3):1417-1424
pubmed: 28314313
Clin Cancer Res. 2004 Jun 1;10(11):3755-62
pubmed: 15173082
BMC Cancer. 2017 May 26;17(1):375
pubmed: 28549420
Am J Surg Pathol. 2019 Oct;43(10):1392-1396
pubmed: 31290758
Head Neck. 2020 Nov;42(11):3206-3217
pubmed: 32613643